Glioblastoma multiforme (GBM) is the most malignant form of brain cancer and remains one of the most aggressive forms of all human cancers with a median survival of just over one year despite multi modality therapy. GBM has been shown to contain cancer stem cells that are drive tumor growth. This finding has led to paradigm shift in developing effective therapies by exploiting tumor stem cell properties and vulnerabilities. A clear understanding of early epigenetic events that contribute to cancer stem cell differentiation and proliferation will be essential to develop pharmacologic strategies to target them. In this proposal, we aim to elucidate genomic regions that are susceptible for epigenetic aberrations in brain tumor stem cells using high throughput tag sequencing. This data will be used to learn how these aberrations lead to deregulation of gene expression and other genomic elements that orchestrate glioblastoma tumorigenesis and pathogenesis. These studies will have a two fold potential impact: a) provide new insights into mechanisms that contribute to gliomagenesis and b) provide sensitive and robust targets for development of rational therapeutic intervention of glioblastoma.

Public Health Relevance

Patients with glioblastoma multiforme face a deadly disease with limited treatment options. Identification of genomic regions susceptible to epigenetic aberrations in brain tumor stem cells holds a great promise for developing effective therapies for aggressive and recurrent glioblastoma. The changes in promoter methylation patterns and the expression level of key genes may have diagnostic, therapeutic or prognostic significance for the successful development of effective treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA135339-01A2
Application #
7658595
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Okano, Paul
Project Start
2009-04-01
Project End
2011-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
1
Fiscal Year
2009
Total Cost
$257,619
Indirect Cost
Name
Swedish Medical Center, First Hill
Department
Type
DUNS #
079264420
City
Seattle
State
WA
Country
United States
Zip Code
98122
Lin, Biaoyang; Lee, Hwahyung; Yoon, Jae-Geun et al. (2015) Global analysis of H3K4me3 and H3K27me3 profiles in glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor suppressor gene. Oncotarget 6:5369-81
Yan, Xiaowei; Ma, Li; Yi, Danielle et al. (2011) A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A 108:1591-6
Ghosh, Dhimankrishna; Yan, Xiaowei; Tian, Qiang (2009) Gene regulatory networks in embryonic stem cells and brain development. Birth Defects Res C Embryo Today 87:182-91